HS-10390
Showing 1 - 25 of 549
IgA Nephropathy, Focal Segmental Glomerulosclerosis Trial in Nanjing (HS-10390 tablet, Placebo tablet)
Recruiting
- IgA Nephropathy
- Focal Segmental Glomerulosclerosis
- HS-10390 tablet
- Placebo tablet
-
Nanjing, Jiangsu, ChinaZhongda Hospital, Affiliated to Southeast University
Jul 12, 2023
s to Diagnose Acute Myocardial Infarction in Elevated Hs-cTnT
Completed
- Acute Myocardial Infarction
- No Intervention
-
Nanjing, Jiangsu, ChinaThe First Affiliated Hospital of Nanjing Medical University
Sep 26, 2023
Switching From Cardiac Troponin I to T
Recruiting
- Acute Coronary Syndrome
- +5 more
- Clinical implementation of hs-cTnT
-
Edinburgh, United KingdomCentre for Cardiovascular Science
Feb 17, 2023
Hidradenitis Suppurativa, Acne Inversa Trial (Nd:YAG laser hair removal, Clindamycin 1 % Topical Lotion)
Not yet recruiting
- Hidradenitis Suppurativa, Acne Inversa
- Nd:YAG laser hair removal
- Clindamycin 1 % Topical Lotion
- (no location specified)
Feb 28, 2023
Nonsmall Cell Lung Cancer Trial in Shanghai (HS-10365 capsules)
Recruiting
- Nonsmall Cell Lung Cancer
- HS-10365 capsules
-
Shanghai, Shanghai, ChinaShanghai Chest Hospital
Nov 22, 2023
Psoriasis Trial in Shanghai (HS-10374 tablets 1mg, HS-10374 tablets 5mg, HS-10374-matched tablets)
Not yet recruiting
- Psoriasis
- HS-10374 tablets 1mg
- +2 more
-
Shanghai, Shanghai, ChinaHuashan Hospital of Fudan University
Oct 8, 2023
HIDRAdenitis Suppurativa and HEART Disease
Enrolling by invitation
- Hidradenitis
- +10 more
-
Hellerup, Copenhagen, DenmarkDepartment of Cardiology, Herlev and Gentofte University Hospita
Aug 4, 2023
NSCLC, Solid Tumor Trial in Tianjin (HS-20117)
Not yet recruiting
- Non-Small Cell Lung Cancer
- Solid Tumor
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
Jul 10, 2023
Hidradenitis Suppurativa Trial in Minneapolis (Fecal Microbiota - lyophilized, Placebo drug)
Not yet recruiting
- Hidradenitis Suppurativa
- Fecal Microbiota - lyophilized
- Placebo drug
-
Minneapolis, MinnesotaUniversity of Minnesota
Oct 2, 2023
Metastasis Castration Resistant Prostate Cancer(mCRPC) Trial (HS-20093)
Not yet recruiting
- Metastasis Castration Resistant Prostate Cancer(mCRPC)
- (no location specified)
Aug 14, 2023
NSCLC Trial (HS-10241+ Almonertinib, Pemetrexed + Cisplatin /Carboplatin)
Not yet recruiting
- Non-Small Cell Lung Cancer
- HS-10241+ Almonertinib
- Pemetrexed + Cisplatin /Carboplatin
- (no location specified)
Oct 29, 2023
Hidradenitis Suppurativa, Quality of Life Trial in Miami (Mindfulness Course, HS Educational Course)
Not yet recruiting
- Hidradenitis Suppurativa
- Quality of Life
- Mindfulness Course
- HS Educational Course
-
Miami, FloridaUniversity of Miami
Jan 18, 2023
CML, Chronic Phase, CML, Accelerated Phase Trial in Wuhan (HS-10382(Part 1: Dose escalation), HS-10382(Part 2: Dose expansion))
Recruiting
- CML, Chronic Phase
- CML, Accelerated Phase
- HS-10382(Part 1: Dose escalation)
- HS-10382(Part 2: Dose expansion)
-
Wuhan, Hubei, ChinaUnion Hospital affiliated to Tongji Medical College of Huazhong
Jan 12, 2023
Head and Neck Squamous Cell Carcinoma Trial (HS-20093)
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- (no location specified)
Aug 17, 2023
Genetic Traits and Linkages in Families
Recruiting
- Hidradenitis Suppurativa
-
Chicago, IllinoisUniversity of Chicago Medicine
Jan 25, 2023
Scar, Hidradenitis Suppurativa Trial (device, procedure, drug)
Not yet recruiting
- Scar
- Hidradenitis Suppurativa
- Triamcinolone Topical
- +2 more
- (no location specified)
Oct 6, 2022
Hidradenitis Suppurativa Trial in Detroit (Laight therapy, NICE V3.1 device)
Completed
- Hidradenitis Suppurativa
- Laight therapy, NICE V3.1 device
-
Detroit, MichiganHenry Ford Hospital Systems- New Center One
Jun 28, 2023
Hidradenitis Suppurativa Trial in Canada, Poland, United States (Izokibep, Placebo to izokibep)
Recruiting
- Hidradenitis Suppurativa
- Izokibep
- Placebo to izokibep
-
Encino, California
- +51 more
Feb 1, 2023
Type 2 Diabetes Trial in Beijing (HS-20094 5mg, HS-20094 10mg, HS-20094 15mg)
Recruiting
- Type 2 Diabetes
- HS-20094 5mg
- +3 more
-
Beijing, Beijing, ChinaPeking University First Hospital
Nov 3, 2023